31 results
8-K
EX-10.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
operations, such as a cybersecurity incident; or one of our key executives, scientists or other personnel may become incapacitated by COVID-19
8-K
EX-10.1
un1qor0u pypbq8
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
xsrwwqzj5 i8j0
16 Mar 22
Prospectus supplement for primary offering
8:00am
S-3
EX-1.2
m19h54olmio0r3p
5 Jun 20
Shelf registration
5:02pm
10-K
nq1 s3dp0
23 Mar 20
Annual report
4:12pm